Available evidence for many prescription drugs comes from clinical trials that often exclude older patients. Real-world evidence (RWE) generated post-approval can provide new evidence on effectiveness and safety for these populations. We sought to understand physicians’ perceptions of clinical trial and RWE for prescribing decisions. To frame the study, we used examples of drugs for heart failure and anticoagulation, which are more like to be prescribed to older adults.
Methods
We conducted an interview study of 15 US physicians specializing in geriatrics, cardiology, or primary care and affiliated with academic medical centers. Interviews were coded using a qualitative thematic analysis approach to construct themes and identify patterns in responses.
Results
All participants described limitations in current believed real-world evidence could help inform patient care and their practice. However, they had concerns about the data. If clinical trial and RWE findings diverged, all would need more information to determine which findings to follow.
Conclusions
Physicians who routinely prescribe to older patients are optimistically cautious about RWE for drugs but would rely on trusted sources, like professional society guidelines, for incorporating it into practice. Therefore, RWE researchers should identify opportunities to work alongside guideline developers and database editors on the practice-relevant interpretation and dissemination of the evidence.
LockettJSaumaSRadziszewskaBBernardMA. Adequacy of inclusion of older adults in NIH-funded phase III clinical trials. J Am Geriatr Soc. 2019;67(2):218-222. doi:10.1111/jgs.15786
2.
PitkalaKHStrandbergTE. Clinical trials in older people. Age Ageing. 2022;51(5):afab282. doi:10.1093/ageing/afab282
3.
CaugheyGEInacioMCBellJSVitryAIShakibS. Inclusion of older people reflective of real-world clinical practice in cardiovascular drug trials. J Am Heart Assoc. 2020;9(21):e016936. doi:10.1161/JAHA.120.016936
4.
BukanKPearce-SladeTEibergM, et al.Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic. Aging Clin Exp Res. 2023;35(5):917-923. doi:10.1007/s40520-023-02380-4
5.
DeJongCCovinskyK. Representation of older adults in cardiovascular disease trials since the inclusion across the lifespan policy. JAMA Intern Med. 2020;180(11):1533-1534. doi:10.1001/jamainternmed.2020.2750
6.
NannaMGChenSTNelsonAJNavarAMPetersonED. Representation of older adults in cardiovascular disease trials since the inclusion across the lifespan policy. JAMA Intern Med. 2020;180(11):1531-1533. doi:10.1001/jamainternmed.2020.2750
7.
PetrovskyDVEthoanLNLoizosM, et al.Key recommendations from the 2021 “inclusion of older adults in clinical research” workshop. J Clin Transl Sci. 2022;6(1):e55. doi:10.1017/cts.2022.1
8.
U.S. Food and Drug Administration. Public Workshop: Evaluating Inclusion and Exclusion Criteria in Clinical Trials. Silver Spring, MD: US Food and Drug Administration, 2018.
GurwitzJH. The exclusion of older people from participation in cardiovascular trials. Virtual Mentor: AMA J Ethics. 2014;16(5):365-368. doi:10.1001/virtualmentor.2014.16.5.pfor1-1405
11.
WangSVSchneeweissSGagneJJ, et al.Using real-world data to extrapolate evidence from randomized controlled trials. Clin Pharmacol Ther. 2019;105(5):1156-1163. doi:10.1002/cpt.1210
12.
WangSVSchneeweissSInitiativeR-D, et al.Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA. 2023;329(16):1376-1385. doi:10.1001/jama.2023.4221
13.
WangSVPinheiroSHuaW, et al.STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;372:m4856. doi:10.1136/bmj.m4856
14.
MakadyAde BoerAHillegeHKlungelOGoettschW. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858-865. doi:10.1016/j.jval.2017.03.008
15.
BergerMLSoxHWillkeRJ, et al.Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health. 2017;20(8):1003-1008. doi:10.1016/j.jval.2017.08.3019
RobertsMHFergusonGT. Real-world evidence: bridging gaps in evidence to guide payer decisions. Pharmacoecon Open. 2021;5(1):3-11. doi:10.1007/s41669-020-00221-y
18.
FeldmanWBWangSVKesselheimAS. Real-world evidence is a vital tool for informing treatment strategies in chronic obstructive pulmonary disease. BMJ. 2025;388:r427. doi:10.1136/bmj.r427
19.
BhattASVaduganathanMSolomonSDSchneeweissSLauffenburgerJCDesaiRJ. Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries. Eur J Heart Fail. 2022;24(9):1506-1515. doi:10.1002/ejhf.2572
20.
OzakiAFKrumholzHMModyFVJackeviciusCA. National trends in the use of sacubitril/valsartan. J Card Fail. 2021;27(8):839-847. doi:10.1016/j.cardfail.2021.05.015
21.
KlonoffDC. The expanding role of real-world evidence trials in health care decision making. J Diabetes Sci Technol. 2020;14(1):174-179. doi:10.1177/1932296819832653
22.
VillinesTCCzirakyMJAminAN. Awareness, knowledge, and utility of RCT data vs RWE: results from a survey of US cardiologists: real-world evidence in clinical decision making. Clin Med Insights Cardiol. 2020;14:1179546820953410. doi:10.1177/1179546820953410
23.
RomanelliRJNoltingLDolginskyMKymEOrricoKB. Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2016;9(2):126-134. doi:10.1161/CIRCOUTCOMES.115.002369
24.
RutherfordOWJonassonCGhanimaWSoderdahlFHalvorsenS. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020;6(2):75-85. doi:10.1093/ehjcvp/pvz086
25.
GueYBloomfieldDFreedholmDLipGYH. Comparing the real-world and clinical trial bleeding rates associated with oral anticoagulation treatment for atrial fibrillation. J Clin Med. 2024;13(8):2277.
26.
CaliffRM. LCZ696: too good to be true?Eur Heart J. 2015;36(7):410-412. doi:10.1093/eurheartj/ehu501
27.
SandhuATHeidenreichPALinJParizoJBhattacharyaJGoldhaber-FiebertJD. Perks and pitfalls of performance-linked reimbursement for novel drugs: the case of sacubitril-valsartan. Circ Cardiovasc Qual Outcomes. 2022;15(1):e007993. doi:10.1161/CIRCOUTCOMES.121.007993
28.
GuestGNameyEChenM. A simple method to assess and report thematic saturation in qualitative research. PLoS One. 2020;15(5):e0232076. doi:10.1371/journal.pone.0232076
29.
BraunVClarkeV. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101. doi:10.1191/1478088706qp063oa
30.
BraunVClarkeV. Thematic analysis. In APA Handbook of Research Methods in Psychology, Vol. 2. Research Designs: Quantitative, Qualitative, Neuropsychological, and Biological. American Psychological Association. 2012;2:pp. 57-71.
31.
SaundersCHSierpeAvon PlessenC, et al.Practical thematic analysis: a guide for multidisciplinary health services research teams engaging in qualitative analysis. BMJ. 2023;381:e074256. doi:10.1136/bmj-2022-074256
32.
KoDLinKJBessetteLG, et al.Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020. JAMA Netw Open. 2022;5(11):e2242964. doi:10.1001/jamanetworkopen.2022.42964
33.
NajafzadehMSchneeweissSChoudhryNKWangSVGagneJJ. Simulation for predicting effectiveness and safety of new cardiovascular drugs in routine care populations. Clin Pharmacol Ther. 2018;104(5):1008-1015. doi:10.1002/cpt.1045
34.
BergerMLSoxHWillkeRJ, et al.Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033-1039. doi:10.1002/pds.4297
35.
FDA. Framework for FDA's Real-World Evidence Program. Silver Spring, MD: U.S. Food and Drug Administration; 2018.
36.
FDA. Considerations for the Use of Real-World Data and Real World Evidence to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry. Silver Spring, MD: US Food and Drug Administration; 2023.
37.
FDA. An Assessment of the Sentinel System (2022 to 2024). Silver Spring, MD; US Food and Drug Administration; 2025.
38.
MasucciLLewisDZhaoJCarterCChanKKWWongWWL. The use of real-world evidence among healthcare payers: a scoping review. Int J Technol Assess Health Care. 2025;41(1):e67. doi:10.1017/S0266462325100445
39.
JaksaAArenaPJ. The potential role of real-world evidence in centers for Medicare & Medicaid services’ future price negotiations: recommendations for a robust framework. J Manag Care Spec Pharm. 2024;30(6):604-607. doi:10.18553/jmcp.2024.30.6.604
40.
JaksaAGibbsLKentS, et al.Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study. BMJ Open. 2022;12(10):e064662. doi:10.1136/bmjopen-2022-064662
41.
Micromedex[Internet]. Micromedex, Inc; 1990.
42.
PublishingE. Dynamic Medical Information Systems LLC, American College of P. DynaMed. Dynamic Medical Information System plus. Ipswich, MA: EBSCO Industries, Inc; 2015.
SteelsSvan StaaTP. The role of real-world data in the development of treatment guidelines: a case study on guideline developers’ opinions about using observational data on antibiotic prescribing in primary care. BMC Health Serv Res. 2019;19(1):942. doi:10.1186/s12913-019-4787-5
45.
AAMC. U.S. Physician Workforce Data Dashboard. Washington, DC: Association of American Medical Colleges; 2023.
46.
GuestGBunceAJohnsonL. How many interviews are enough?Field Methods. 2016;18(1):59-82. doi:10.1177/1525822x05279903
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
